A pre-engineered version of Adagio’s lead drug candidate, ADG20, protected against SARS-CoV and SARS-CoV-2—the virus that causes COVID-19—in mouse models. In lab tests, the drug also neutralized WIV-1 and SHC014, two related coronaviruses known to be circulating in bats.